U.S. Could Authorize Novavax Covid Vaccine—An MRNA Alternative—In February, CEO Says

Novavax’s Covid-19 vaccine, already available for use in 170 countries and most well-known for being a non-mRNA vaccine alternative, could be approved for use in the U.S. in February and in up to 10 other countries within 90 days, CEO Stanley Erck told CNBC Monday.